Valentin Petrich
Group Leader - Chemistry Heidelberg Pharma
Seminars
Thursday 21st August 2025
Novel: Exatecan-based ADC Using HDP’s Innovative Multimeric Linker Platform
12:00 pm
- A new multimeric linker platform facilitated the development of HDP-201, an ADC with exatecan as payload, as novel therapeutic modality for the treatment of solid tumors
- The role of solubility enhancers in enabling site-specific coupling to cysteines, leading to stable, potent, and well tolerated ADCs
- HDP-201 shows dose-dependent tumor regression in vivo and enhanced anti-tumor efficacy following multiple doses
